Inventor
YIBIN ZENG
Inventor
US
Overview
Patents· 22 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes29%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations29%
C07DHeterocyclic compounds28%
C07BGeneral methods of organic chemistry4%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium3%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
C07CAcyclic or carbocyclic compounds1%
C07KPeptides1%
Y02ATechnologies for adaptation to climate change1%
PatentTitleYear
12,533,354Triaryl compounds for treatment of PD-L1 diseases202612,497,383Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases202512,448,373Azetidinyl-acetamides as CXCR7 inhibitors202512,371,433Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases202512,268,675Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors202512,054,484Substituted tetrahydropyrans as CCR2 modulators202411,883,391Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies202411,866,429Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases202411,834,452CXCR7 antagonists202311,807,609Deuterated compounds as immunomodulators202311,773,0916-5 fused rings as C5a inhibitors202311,713,307Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases202311,608,336Prodrugs of fused-bicyclic C5aR antagonists202311,603,356Amorphous form of a complement component C5a receptor202311,485,737Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors202211,478,460Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors202211,479,5535-5 fused rings as C5a inhibitors202211,433,061Heteroaryl sulfonamides and CCR2/CCR9202211,427,541Salt forms of a complement component C5A receptor202211,384,0796-5 fused rings as C5a inhibitors202211,266,643Triaryl compounds for treatment of PD-L1 diseases202211,254,695Soluble C5aR antagonists2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2026Patents assigned to CHEMOCENTRYX INC (22)· patent assignee history
2022–2026Based in US· patent location history
2025Patents assigned to AMGEN INC (2)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| CHEMOCENTRYX INC | 22 | 2022–2026 |
| AMGEN INC | 2 | 2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 22 | 2022–2026 |